Brett Haumann

Dr. Brett Haumann joined ReViral in January 2022 as Chief Medical Officer. He joins the ReViral team after spending the past 7 years as Chief Medical Officer and Senior Vice President of Development at Theravance Biopharma. During his time at Theravance, he oversaw a multi-functional organization developing a broad portfolio of novel assets in multiple therapeutic areas including pulmonology, neurology, gastroenterology, immunology, cardiorenal and infectious diseases across all phases of development. He spent time in both European and US subsidiaries of the company and oversaw the successful development and first-cycle FDA approval of revefenacin (YUPELRI®) for the treatment of COPD. Previously, Brett served as Chief Medical Officer at Circassia Pharmaceuticals, prior to which he spent more than 15 years in senior development roles at GlaxoSmithKline (GSK), including as Vice President of Clinical Development where he served as the global Medicines Development Leader, spearheading the successful development and approval of RELVAR®/BREO® for the treatment of asthma and COPD.

Brett has also served as a non-executive director on a number of private and public boards in Europe and the US, including most recently as the Head of the R&D Committee on the Board of Aimmune Therapeutics, prior to its acquisition by Nestlé in 2020.

He holds an M.D. from Witwatersrand University in South Africa and an MBA from The Open University in the UK.